Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03907917 · ClinicalTrials.gov registry record · NA

Transcranial Direct Current Stimulation and Fear Extinction

A NA study, sponsored by Thomas Adams.

Completed
Registry status
NA
Development phase
67
Enrollment target

NCT03907917 is a NA study that has completed, run by Thomas Adams. The registered enrollment target is 67 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03907917, a NA study, has completed, sponsored by Thomas Adams.

COMPLETED
Registry status
NA
Development phase
67 participants
Enrollment target

Study Summary

Psychiatric disorders characterized by pathological fear and anxiety are common and often disabling. Despite their limitations, exposure therapies are among the most efficacious treatments for these disorders. Extinction learning is thought to be a core mechanism of therapeutic exposure. Extinction learning is mediated by a well-defined circuit encompassing the medial prefrontal cortex (mPFC), amygdala, and hippocampus. This raises the exciting possibility that direct engagement of this circuitry might enhance the response to therapeutic exposure. Transcranial direct current stimulation (tDCS) is a neuromodulation technology that can augment brain plasticity, learning, and memory. The proposed study will evaluate whether tDCS can engage extinction circuitry, and improve extinction learning and memory. This study will enroll psychiatrically healthy volunteers to test whether tDCS applied to the mPFC can augment spontaneous mPFC activity, engagement of extinction circuitry during extinction learning and recall, and classically-conditioned extinction learning and memory. Healthy volunteers will complete a standardized, three-day fear conditioning and extinction learning and memory task. On day 1, participants will complete a fear conditioning task. On day 2, participants will receive sham (placebo) or active tDCS prior to completing a fear extinction learning task. On day 3, participants will complete an extinction recall task. Electrodermal activity and heart rate will be continuously monitored during the conditioning and extinction procedures to assess autonomic arousal. All procedures will be completed in a magnetic resonance imaging (MRI) scanner; imaging data will be collected before and after tDCS and during all conditioning and extinction procedures.

Interventions

  • DEVICE tDCS

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2019-04-09
Est. Completion 2023-06-01
Phase NA

Sponsor

Thomas Adams

2 total trials

What the Registry Record Tells You About NCT03907917

The ClinicalTrials.gov registry entry for NCT03907917 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Adams, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which tDCS is the first listed.

NCT03907917 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03907917 about?

NCT03907917 is a clinical study titled "Transcranial Direct Current Stimulation and Fear Extinction". Psychiatric disorders characterized by pathological fear and anxiety are common and often disabling. Despite their limitations, exposure therapies are among the most efficacious treatments for these disorders. Extinction learning is thought to be a core mechanism of therapeutic exposure. Extinction ...

What is the current status of trial NCT03907917?

This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2019-04-09. Estimated completion is 2023-06-01.

What interventions are being tested in trial NCT03907917?

The interventions under investigation include: tDCS (DEVICE).

Who is sponsoring clinical trial NCT03907917?

This trial is sponsored by Thomas Adams, which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.